View updated information about our visitor policy  »
Book an appointment at our COVID-19 Assessment Centre (new location) »

Inventing the Future of Health Care for Ontario and Beyond: Strategic Plan 2018-21
Share:  
|

Click here to read a text-only version of this infographic

Strategic Direction 1: Personalized and Precise Treatments

Operational Excellence

Indicator: Alternate Level of Care (ALC) rate in acute care medical and surgical beds (%)
2019/20 Year to Date Target: ≤13%
Q1 2019/20 Results: 13.0% (reached target)
Q2 2019/20 Results: 12.5% (reached target)
Q3 2019/20 Results: 12.7% (reached target)
Q4 2019/20 Results: 12.8%

Indicator: Median Emergency Department LOS for Admitted patients (Hours)
2019/20 Year to Date Target: ≤14.5 hours
Q1 2019/20 Results: 17.5 hours
Q2 2019/20 Results: 15.5 hours
Q3 2019/20 Results: 16.1 hours
Q4 2019/20 Results: 13.1 hours (reached target)

Indicator: Answer to the question: “Does Sunnybrook have a balanced budget and is it achieving or exceeding its balanced budget financial position?” (Yes/No)
2019/20 Year to Date Target: Yes
2018/19 Results: Yes (reached target)
Q1 2019/20 Results: Yes (reached target)
Q2 2019/20 Results: Yes (reached target)
Q3 2019/20 Results: Yes (reached target)
Q4 2019/20 Results: Yes (reached target)

Indicator: eDischarge Summaries completed within 48 hours (%)
2019/20 Year to Date Target: >85%
Q1 2019/20 Results: 78.7%
Q2 2019/20 Results: 78.1%
Q3 2019/20 Results: 78.7%
Q4 2019/20 Results: 81.0%

Indicator: Patient Response to "How often did staff work with you to act on what was important to you?" (%)
2019/20 Year to Date Target: ≥67.1%
Q1 2019/20 Results: 68.2% (reached target)
Q2 2019/20 Results: 63.0%
Q3 2019/20 Results: 62.7%
Q4 2019/20 Results: 62.7%

Strategic Direction 1: Personalized & Precise Treatments

Goal 1: Advance support for discovery and technology development in molecular and image guided diagnostics and therapeutics; and population health research and analytics
Performance Indicator: Number of pre-clinical trials initiated in Personalized & Precise Treatments (PPT) (#)
2019/20 Quarterly Target: 4
Q1 2019/20 Results: 3
Q2 2019/20 Results: 4 (reached target)
Q3 2019/20 Results: 7 (reached target)
Q4 2019/20 Results: 5 (reached target)

Goal 2: Lead in the translation and implementation of new personalized and precise diagnostics and therapeutics and minimally invasive interventions
Performance Indicator: Number of clinical trials initiated in Personalized & Precise Treatments (PPT) (#)
2019/20 Quarterly Target: 4.25
Q1 2019/20 Results: 2
Q2 2019/20 Results: 5 (reached target)
Q3 2019/20 Results: 5 (reached target)
Q4 2019/20 Results: 5 (reached target)

Goal 3: Lead in the adoption and spread of new models of care in personalized and precise diagnostics and therapeutics and minimally invasive interventions
Performance Indicator: Number of PPT interventions implemented at Sunnybrook (#)
2019/20 Target (cumulative): 2
Q1 2019/20 Results: 1
Q2 2019/20 Results (cumulative): 1
Q3 2019/20 Results (cumulative): 1
Q4 2019/20 Results (cumulative): 2 (reached target)

Illustrating Progress

First outpatient gynaecological brachytherapy

Urszula Waryan-Jasinska became the first patient in Sunnybrook’s MR-Brachytherapy Suite to receive electromagnetically guided interstitial brachytherapy — and go home the same day.

Brachytherapy strikes tumours with high doses of radiation and is used in the treatment of prostate, breast and gynecological cancers.

For interstitial brachytherapy for gynecological cancers, a cylinder and applicators that look like needles are inserted into the tumour, around the vagina, cervix or uterus. The applicators are attached to a treatment unit that moves a radiation source precisely through the applicators to destroy the tumour while avoiding harm to the patient’s normal tissues.

Sunnybrook’s MR-Brachytherapy Suite, which is made up of an operating room, radiation bunker and MRI machine for imaging, allows for a much more streamlined approach.

“Having the suite allows us to image MR in real time for optimal applicator placement, planning and even treatment. The patient doesn’t have to be awake with the applicator in place and instead can have the treatment all done while under anesthesia,” Dr. Eric Leung, radiation oncologist, explained.

In addition, Sunnybrook is testing electromagnet technology that helps guide the needle placement for increased precision during the procedure.


Next »